Effect of recombinant human growth hormone and insulin-like growth factor-1 administration on IGF-1 and IGF-binding protein-3 levels in brain injury

Pharmacotherapy

Volumn 19, Issue 12, 1999, Pages 1432-1436

  Rockich, Kevin T ^a   Hatton, Jimmi C ^a   Kryscio, Richard J ^a   Young, Byron A ^a   Blouin, Robert A ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

HUMAN GROWTH HORMONE; SOMATOMEDIN BINDING PROTEIN 3; SOMATOMEDIN C;

ADULT; ARTICLE; BRAIN INJURY; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFECT; HORMONAL REGULATION; HORMONE BLOOD LEVEL; HORMONE PROTEIN COMPLEX; HUMAN; NEGATIVE FEEDBACK; PROTEIN BINDING; RANDOMIZED CONTROLLED TRIAL; REGULATORY MECHANISM; SUBCUTANEOUS DRUG ADMINISTRATION;

EID: 0032708766     PISSN: 02770008     EISSN: None     Source Type: Journal    
DOI: 10.1592/phco.19.18.1432.30891     Document Type: Article

References (30)

1. U.S. Department of Health and Human Services, Public Health Services, Centers for Disease Control and Prevention, National Center for Health Statistics. Vital statistics of the United States. Hyattsville, MD: Author, 1982.
2. Blaine CW, Krause GS. Brain injury and repair mechanisms: the potential for pharmacological therapy in closed-head trauma. Ann Emerg Med 1993;22:970-9.
3. Doberstein CE, Hovda DA, Becker DP. Clinical considerations in the reduction of secondary brain injury. Ann Emerg Med 1993;22:993-7.
4. Gennarelli TA. Mechanisms of brain injury. J Emerg Med 1993;1:5-11.
5. Wojnar MM, Fin J, Frost RA, Gelato MC, Lang CH. Alterations in the insulin-like growth factor system in trauma patients. Am J Physiol 1995;268:R970-7.
6. Jeevanandam M, Holaday NJ, Shamos RF. Acute insulin-like growth factor-1 deficiency in multiple trauma victims. Clin Nutr 1992;11:352-7.
7. Petersen SR, Jeevanandam M, Holaday NJ. Adjuvant recombinant human growth hormone stimulates insulin-like growth factor binding protein-3 secretion in critically ill trauma patients. J Trauma 1995;39:295-300.
8. Jeevanandam M, Ramias L, Shamos RF, Schiller WR. Decreased growth hormone levels in the catabolic phase of severe injury. Surgery 1992:111:495-502.
9. Daughaday WH, Rotwein P. Insulin-like growth factor I and II. Peptide, messenger ribonucleic acid and gene structures, serum, and tissue concentrations. Endocrinol Rev 1989;10:68-91.
10. Rechler MM, Brown AL. Insulin-like growth factor binding proteins: gene structure and expression. Growth Regul 1992;2:55-68.
11. Baxter RC, Martin JL, Beniac VA. High molecular weight insulin-like growth factor binding protein complex. J Biol Chem 1989;264:11843-8.
12. Hintz RL. The annals of IGF binding proteins: into the next millennium. Prog Growth Factor Res 1995;6:79-89.
13. Kelley KM, Oh Y, Gargosky SE, et al. Insulin-like growth factor-binding proteins (IGFBPs) and their regulatory dynamics. Int J Biochem Cell Biol 1996;28:619-37.
14. Rechler MW. Insulin-like growth factor binding proteins. Vitam Horm 1993;47:1-114.
15. 1251-labeled IGF-1 in protein-restricted rats. Am J Physiol 1992;262:E406-11.
16. Hatton J, Rapp RP, Kudsk KA, et al. Intravenous insulin-like growth factor-1 (IGF-1) in moderate-to-severe head injury: a phase II safety and efficacy trial. J Neurosurg 1997;86:779-86.
17. Kupfer SR, Underwood LE, Baxter RC, Clemmons DR. Enhancement of the anabolic effects of growth hormone and insulin-like growth factor-1 by use of both agents simultaneously. J Clin Invest 1993;91:391-6.
18. Baxter RC, Martin JL. Structure of the m.w. 140,000 growth hormone-dependent insulin-like growth factor binding protein complex: determination by reconstitution and affinity-labeling. Proc Natl Acad Sci USA 1989;86:6898-6902.
19. Yamamoto H, Murphy LJ. N-Terminal truncated insulin-like growth factor-1 in human urine. J Clin Endocrinol Metab 1995:80:1179-83.
20. D'Ercole AJ, Decedue CJ, Furlanetto RW, Underwood LE, Van Wyk JJ. Evidence that somatomedin-C is degraded by the kidney and inhibits insulin degradation. Endocrinology 1977;101:577-86.
21. Tonshoff B, Blum WF, Vickers M, Kurilenko S, Mehls O, Ritz E. Quantification of urinary IGF-1 and IGFBP-3 in healthy volunteers before and after stimulation with recombinant human growth hormone. Eur J Endocrinol 1995;132:433-7.
22. Gillette JR. Overview of drug-protein binding. Ann NY Acad Sci 1973;226:6-17.
23. Odar-Cederlof I, Borga O. Kinetics of diphenylhydantoin in uraemic patients: consequences of decreased plasma protein binding. Eur J Clin Pharmacol 1974;7:31-7.
24. Rabkin R, Fervenza FC, Maidment H, et al. Pharmacokinetics of insulin-like growth factor-1 in advanced chronic renal failure. Kidney Int 1996;49:1134-40.
25. Busby WH, Hossenlopp P, Binoux M, Clemmons DR. Purified preparations of the amniotic fluid IGF binding protein contain multimeric forms that are biologically active. Endocrinology 1989;125:773-7.
26. Clemmons DR, Elgin RG, Han VM, Casella SJ, D'Ercole AJ, Van JJ. Cultured fibroblast monolayers secrete a protein that alters the cellular binding of somatomedin-C/ IGF-1. J Clin Invest 1986;77:1548-56.
27. McCusker RH, Camacho-Hubner C, Bayne ML, Cascieri MA, Clemmons DR. Insulin-like growth factor (IGF) binding to human fibroblasts and glioblastoma cells: the modulating effect of cell released IGF binding proteins (IGFBPs). J Cell Physiol 1990;144:244-53.
28. Elgin RG, Busby WH, Clemmons DR. An insulin-like growth factor binding protein enhances the biological response to IGF-1. Proc Natl Sci USA 1987;84:3254-8.
29. Blum WF, Jenne EW, Reppin F, Kietzmann K, Ranke MB, Bierich JR. Insulin-like growth factor 1 (IGF-1) binding protein complex is a better mitogen than free IGF-1. Endocrinology 1989;125:766-72.
30. Jones JI, Clemmons DR. Insulin-like growth factors and their binding proteins: biological actions. Endocrinol Rev 1995;16:3-34.